Therefore, implementing anti-CD47 antibodies to anti-HER2 treatment of HER2+ breast cancer may be beneficial in treating those patients whose cancers have progressed after anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.